drugset / Trial / NCT00626288

Mesalazine Therapy in Patients With Irritable Bowel Syndrome

NCT00626288 ↗

Phase 3 Completed 187 enrolled SOFAR S.p.A.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether Mesalazine is effective in the treatment of the abdominal discomfort or pain of Irritable Bowel Syndrome patients.

Timeline

Start
2007-12
Primary completion
2012-03
Completion
2012-07

Outcome

Missed primary endpoint

paper For the primary endpoint, the responder patients were 68.6% in the mesalazine group versus 67.4% in the placebo group (p=0.870; 95% CI -12.8 to 15.1). PMID 25533646 ↗

paper Mesalazine treatment was not superior than placebo on the study primary endpoint. PMID 25533646 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesalamine Small molecule 800 mg —